InsidersTradesSigma
Ainos, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Follow the Ainos, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Ainos, Inc. has logged 101 public disclosures. The latest transaction was reported on 9 June 2026 (Acquisition). Among the most active insiders: lee ting-chuan. Every trade is openly available.
101
Insider Decl.
0
Thresholds
€1m
13 ops.
Buy Volume
€12m
19 ops.
Sell Volume
30Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 9 June 2026
Declarations101 total
3,500 shares@ US$2.050.8% of flowCommon StockSEC:0001493152-26-027881:0
Ideal exit: 2 Mar 2027 (T+270)
2,000 shares@ US$2.130.5% of flowCommon StockSEC:0001493152-26-027488:0
Ideal exit: 28 Feb 2027 (T+270)
250 shares@ US$2.300.1% of flowCommon StockSEC:0001493152-26-026617:0
Ideal exit: 22 Feb 2027 (T+270)
2,000 shares@ US$2.000.5% of flowCommon StockSEC:0001493152-26-026361:0
Ideal exit: 21 Feb 2027 (T+270)
1,082 shares@ US$1.550.2% of flowCommon StockSEC:0001493152-26-025482:0
27,718 shares@ US$1.877.1% of flowCommon StockSEC:0001493152-26-025482:1
41,000 shares@ US$2.36100.0% of flowCommon StockSEC:0001493152-26-025484:0
109,988 shares@ US$1.9017.9% of flowCommon StockSEC:0001493152-26-025486:0
9,302 shares@ US$1.571.3% of flowCommon StockSEC:0001493152-26-025246:1
9,000 shares@ US$1.561.2% of flowCommon StockSEC:0001493152-26-025246:0
100 shares@ US$1.750.0% of flowCommon StockSEC:0001493152-26-020893:0
Ideal exit: 24 Jan 2027 (T+270)
200 shares@ US$1.680.0% of flowCommon StockSEC:0001493152-26-020893:1
Ideal exit: 25 Jan 2027 (T+270)
570,000 shares@ US$1.6143.6% of flowCommon StockSEC:0001493152-26-017844:0
300,000 shares@ US$1.6116.7% of flowCommon StockSEC:0001493152-26-017846:0
330,000 shares@ US$1.6141.7% of flowCommon StockSEC:0001493152-26-017859:0
7,000 shares@ US$3.59Common StockSEC:0001493152-25-017424:0
2,000 shares@ US$3.585Common StockSEC:0001493152-25-017140:0
1,006 shares@ US$3.51672.4% of flowCommon StockSEC:0001493152-25-016691:0
11,191 shares@ US$2.43519.0% of flowCommon StockSEC:0001641172-25-022587:0
7,001 shares@ US$2.803316.9% of flowCommon StockSEC:0001493152-25-011320:0
2,894 shares@ US$0.510.1% of flowCommon StockSEC:0001641172-25-016892:0
7,000 shares@ US$0.50280.3% of flowCommon StockSEC:0001641172-25-016890:0
29,476 sharesCommon StockSEC:0001641172-25-016497:0
29,476 sharesCommon Stock, par value $0.01 per shareSEC:0000950103-25-007790:0
Ideal exit: 20 Mar 2026 (T+270)
5,000 shares@ US$0.52170.2% of flowCommon StockSEC:0001641172-25-016172:0
25 of 101 declarations
About Ainos, Inc.
Ainos, Inc. is a U.S.-based healthcare and medtech company listed on NASDAQ in the United States under the symbols AIMD and AIMDW. For French, Belgian, and Swiss investors, it is best viewed as a small-cap R&D-driven name at the intersection of biotechnology, diagnostics, and applied artificial intelligence. The company traces its roots back to 1984, when it was founded around low-dose interferon alpha research. Over time, Ainos expanded and has more recently repositioned itself as a diversified medtech platform centered on three business pillars: low-dose interferon therapeutics, point-of-care diagnostic devices, and its proprietary AI Nose platform, which is designed to convert odor signals into machine-readable data for AI applications. ([ainos.com](https://www.ainos.com/?utm_source=openai)) Ainos’ U.S. operating headquarters is now in Houston, Texas, following an announced relocation from San Diego. The company also maintains a Taiwan presence, reflecting a bi-regional operating model that combines clinical development, intellectual property generation, and industrial partnerships. Ainos says it holds more than 60 patents in total, including over 50 digital nose-related patents, which is central to its differentiation in a niche and still early-stage technology category. ([ainos.com](https://ainos.com/news_view/89?utm_source=openai)) From a product standpoint, Ainos is developing and/or commercializing several product families: VELDONA, its low-dose oral interferon program; AI Nose, its scent-intelligence platform; and diagnostic applications such as Ainos Flora, Ainos Pen, antigen test kits, and other point-of-care tools. The company’s competitive position is that of a specialized innovator rather than a scaled commercial healthcare platform. Its strategy is aimed at markets with potentially large addressable opportunities but relatively low current penetration, including hygiene monitoring, industrial environments, connected healthcare, and selected clinical-use cases. ([ainos.com](https://www.ainos.com/?utm_source=openai)) Recent corporate developments have been centered on the commercialization push for AI Nose. In 2025, Ainos launched its first commercial AI Nose module and announced pilot and partnership activity in Japan and with ASE Technology Holding, including a reported ambition to deploy up to 15,000 units across selected sites. In May 2026, the company said execution on AI Nose was advancing in semiconductor and healthcare infrastructure settings, indicating movement from validation toward broader deployment readiness. For investors, Ainos remains a highly speculative transformation story, dependent on execution, future financing, and the ability to convert intellectual property into recurring revenue streams. ([ainos.com](https://ainos.com/news_view/78?utm_source=openai))
